The most comfortable women's running shoes for 2025
Best overall women's running shoes
More comfortable running shoes for women we loved
How we chose the most comfortable women's running shoes
Factors to consider when choosing comfortable women's running shoes
FAQs
Meet our experts
Update, Jun. 23, 2025: We checked all product prices and availability. Our number one pick for best comfortable running shoes for women remains unchanged.
(back to top)
(back to top)
To figure out which women's running shoes were the best of the best, we consulted a mix of podiatrists, fitness experts, marathoners, running coaches and our own running-obsessed shopping editors. They weighed in on what to look for when picking the right running shoes for different needs. We also polled this crew to find out which options are their favorites — because there's nothing like a firsthand recommendation! After reviewing hundreds of contenders, we came down to 11 final candidates.
(back to top)
Comfort: Like any shoe, comfort is key. You'll want to find a pair with ample cushioning and support to prevent injuries and ensure your feet won't hurt after wearing them, especially if you plan on wearing them for miles.
Traction: "Depending on where you plan to run (trail vs. road), the shoe's traction should provide stability and grip suitable for the terrain", NASM-certified personal trainer, Andrew White tells us. Stephanie Holbrook, Level 1 USA triathlon coach, agrees telling us you want to choose running shoes with a sole that provides a good grip on various surfaces. "Look for shoes with a patterned sole or rubber outsole for optimal traction," she tells us.
Support: According to Dr. Matt Tanneberg, a Chiropractor and Certified strength and conditioning specialist (CSCS) supportive sneakers are necessary to alleviate some of the pressure being put on their feet from the constant impact of running, especially if you have flatter feet. Supportive shoes "will also help to take some of the pressure off of the surrounding joints of the leg, as well: the ankles, knees and hips," he says.
Cushioning: "Comfort and shock absorption depends on a good cushioned and molded insole," Gregory Alvarez, DPM, FACFAS, and Podiatrist at the Ankle & Foot Centers of America tells us. The correct amount of cushioning provides shock absorption from the repetitive pounding that your feet will undergo as you run.
Weight: If you're trying to hit a new personal goal or trying to increase your speed a lightweight sneaker is key. "Lighter-weight models may contribute to better performance, especially when it comes to racing; however, lightweight shoes should not come at the expense of stability," Dr. Alvarez tells us. So when choosing a lightweight running shoe, you also want to make sure the sneaker is durable and structured enough to keep your foot stable and supported.
(back to top)
While you may think any old running shoe will work for everything from light jogs to long marathons, think again. There are actually a variety of types of running shoes to choose from depending on the activity level. White tells us if you're hitting trails with uneven terrains, you should opt for a pair of trail runners as they "Feature rugged soles for better grip and stability on off-road terrains."
If you're just getting into running or looking for a pair to go on short everyday runs, you should invest in a pair of everyday trainers as they are "versatile and durable enough for regular training sessions as well as long-distance runs," says Dr. Alvarez. He also suggests investing in racing flats if you're tackling a marathon or long-distance run because they are "built to maximize speed by minimizing weight and padding."
Marathoner and running trainer, Carleth Keys recommends opting for either a half-size or a full-size larger, depending on the brand. "This is because your feet tend to swell after running for extended periods," she tells us. Kim Clark, marathoner and running coach agrees telling us, "You need to have space in the front so your toes aren't getting banged up against the shoe and allow your foot to flex while running, and to allow for swelling when you run! I size up a full size from my casual shoes!"
According to New York-based podiatrist and foot surgeon, Dr. Hillary Brenner "Running shoes have more cushion to absorb the higher impact of activity." Plus they are usually designed to be lightweight for speed, whereas walking shoes are heavier to provide more stability. "Walking shoes are more flexible at the forefoot whereas running shoes have flexibility throughout the shoe to accommodate for the variety of running patterns," she adds.
There are a few simple ways you can keep your running shoes in tip-top shape. Holbrook recommends wiping your sneakers with a clean cloth to remove any dirt, sweat or debris after every workout. "If your shoes are particularly dirty, you can use a soft-bristled brush and mild soap to clean them. Avoid using harsh chemicals or bleach, as they can damage the material of your shoes," she adds.
Airing out your shoes is also helpful as it can prevent the buildup of bacteria and odor. "Remove the insoles and let them dry separately. You can also stuff your shoes with newspaper to help absorb moisture and speed up the drying process," says Holbrook. And be sure to store them in a cool, dry place when they aren't in use. "Avoid leaving them in direct sunlight or in a damp environment, as this can damage the material and cause odor. You can also use shoe trees or inserts to help maintain their shape," she added.
Another helpful tip is to check the manufacturer label as some gym shoes are now machine-washable, which would make keeping them clean even easier.
Clark says the key to judging when a running shoe needs to be replaced is based on mileage and not the lifespan of the shoe. "Most running shoes will get about 200-300 miles before they aren't absorbing shock well anymore, and some shoes with more cushioning will get more like 400-500."
Her biggest tip for extending the life of your running shoes is to wear them only for running and don't wear them for other types of workouts or running errands. White also suggests rotating between two pairs of running shoes if you run frequently. "This extends the life of each pair and helps reduce the risk of injury by varying the load and stress on your legs and feet. Different shoes can slightly alter how you run, which can benefit your muscles and joints," he tells us.
(back to top)
Julie Lohre, women's fitness expert, IFBB fitness pro athlete and certified personal trainer
Stephanie Holbrook, Level 1 USA triathlon coach, Level 2 USA cycling coach, Pose Method running technique specialist
Andrew White, NASM-certified personal trainer
Gregory Alvarez, DPM, FACFAS, and Podiatrist at the Ankle & Foot Centers of America
Carleth Keys, Marathoner and running trainer
Kim Clark, Marathoner and running coach
Dr. Matt Tanneberg, Chiropractor and Certified strength and conditioning specialist (CSCS) in Scottsdale, AZ
Dr. Elizabeth Daughtry, DPM, FACFAS
Dr. Hillary Brenner, New York-based podiatrist and foot surgeon
(back to top)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille


Time Business News
13 hours ago
- Time Business News
BrainSim-X Launches Developer Platform for Neural Simulation Data
BrainSim-X announced the launch of a developer access program that allows researchers and app developers to integrate brain simulation data into their applications. More information about the platform is available at their official website . The Bangalore-based research initiative said the platform will focus on medical applications, particularly epilepsy research and neurological treatment development. Unlike typical API services, BrainSim-X requires developers to submit applications explaining their intended use cases before gaining access to the platform. Interested developers can request API credentials through their secure portal. The approval process takes approximately one week, with the organization reviewing each application to ensure it aligns with their medical research focus. One developer who has used the platform for three months described it as providing detailed neural activity data that requires significant technical expertise to implement properly. A detailed account of this developer's experience can be found in their comprehensive review . 'The platform generates large amounts of data that require powerful computing resources,' the developer said. 'It's designed for serious medical research rather than general app development.' The organization provides documentation and support for developers working on brain-computer interfaces, neuroscience research projects, and medical applications. Their research findings are available for review in published papers. Real-time data access became available recently, allowing developers to integrate live neural simulation feeds into their applications. The platform is intended for researchers studying brain activity patterns, testing neurological treatments, and developing diagnostic tools. BrainSim-X operates the service through a secure API that provides access to neural simulation data generated by their brain modeling platform. Technical requirements include high-memory computing systems capable of processing large neural datasets. Additional technical insights about the platform's capabilities can be found in this technical analysis . The research initiative says the developer program represents part of their commitment to making brain simulation technology accessible to the global research community. Applications are evaluated based on their potential contribution to medical research and neurological treatment development. BrainSim-X has not disclosed revenue generated from the developer platform, stating that funds support ongoing research activities. The organization expects demand for the platform to grow as more researchers learn about neural simulation applications in medical research. Future platform updates will include enhanced simulation capabilities and additional tools for analyzing neural activity patterns. BrainSim-X says the developer program differentiates it from commercial AI companies by focusing on open research collaboration rather than proprietary technology development. The platform supports research into cognitive enhancement, educational technology, and advanced diagnostic systems. Developers interested in accessing the platform must demonstrate relevant research experience and explain how they plan to use neural simulation data in their projects. BrainSim-X provides training resources to help developers understand neuroscience concepts necessary for effectively using the platform. The organization says it will continue expanding the developer program while maintaining focus on medical and scientific applications. Related Resources TIME BUSINESS NEWS

Associated Press
15 hours ago
- Associated Press
Major Health Insurers Slash Prior Authorization Requirements, Transforming the PA Technology Landscape
Black Book Research identifies Cohere Health, Innovaccer, and Waystar among leading vendors rapidly adapting to new industry rules. NEW YORK CITY, NY / ACCESS Newswire / July 26, 2025 / U.S. healthcare is undergoing a pivotal shift as major insurers-led by UnitedHealthcare and Humana-begin to significantly reduce or eliminate prior authorization (PA) requirements for hundreds of routine procedures. Accelerated by federal policy, provider frustration, and consumer demands for timely access to care, these sweeping changes signal a new era in PA technology and operations, according to a July 2025 flash survey conducted by Black Book Research. Industry Drivers: Regulatory Action Meets Provider and Consumer Pressure Insurers covering over 250 million Americans have committed to streamlining or removing PA burdens by the end of 2026. This is partly driven by the Centers for Medicare & Medicaid Services (CMS), which is launching a pilot program in six states in January 2026 requiring faster, more transparent prior authorizations for select Medicare services. CMS has also announced national response time standards for Medicare Advantage plans, further intensifying the need for automation and interoperability in PA processes. Key Survey Insights from the Field Black Book Research's flash survey compiled viewpoints from: 24 IT leaders representing the top 10 PA vendors; 108 managed care and health plan IT and operational decision-makers; 142 healthcare providers and administrative leaders; and 100 healthcare consumers with recent PA experiences. Notable Findings: 84% of managed care executives support reducing PA requirements 96% of healthcare providers report improved workflows and lower administrative burdens 99% of consumers favor eliminating PA for routine care; 83% say they've experienced harmful care delays 67% of health plans expect to reevaluate or end contracts with existing PA vendors by 2026 Additional Observations: 90% of providers foresee broad adoption of interoperable PA tools by 2027 94% of payers plan substantial investment in AI-based PA platforms 100% of consumers prefer providers with automated and transparent PA processes 96% of PA vendor executives acknowledge their current solutions require modernization within two years __________ Vendors Rapidly Adapting and Leading the Innovation Curve: Client Top KPI Scores Black Book highlights the top-performing vendors already making critical advancements to align with industry shifts: Cohere Health - Excels in AI-based automation, payer-provider integration, and CMS-aligned interoperability Innovaccer - Offers strong EHR integration and regulatory compliance dashboards for PA workflows Waystar - Enhancing its Auth Accelerate platform for real-time eligibility checks and exception handling ScribeRunner - Developing dynamic auto-approval rulesets and real-time tracking modules CoverMyMeds - Expanding AI-powered real-time authorizations for both pharmacy and medical benefits Change Healthcare - Transitioning legacy infrastructure with modular FHIR APIs for automated decision-making Availity - Driving advanced API adoption and digital submission channels PriorAuthNow (Rhyme) - Connecting providers and payers through real-time electronic submission with limited manual effort Black Book's Q1-Q2 client satisfaction rankings show these vendors excelled across 18 qualitative KPIs for PA technology. Cohere Health earned the highest overall honors, with MCG Health, eviCore Healthcare, Agadia, Infinx, and Availity also receiving good marks. Onyx led in FHIR-based PA platform innovation. Detailed competitive intelligence reports are available in the Black Book research store. __________ Vendors Facing Existential Threats in the New Era Not all companies are poised for success. Several previously top-rated PA vendors now face considerable risk due to outdated systems and slow adaptability: eviCore Healthcare - Still dependent on manual review processes, with limited AI capabilities HealthHelp (WNS) - Lagging behind in interoperability and modern payer integration PriorAuthNow (Rhyme) - Despite innovation efforts, struggles with scalable real-time API integration threaten its long-term viability _________ Looking Ahead: A Positive Outlook for Adaptive Vendors While legacy vendors must evolve rapidly or risk market exit, the broader outlook for PA tech is optimistic. Companies investing in automated, intelligent, and interoperable systems are well-positioned to thrive. 'The future of prior authorization is transparent, automated, and fully integrated into clinical workflows,' said Doug Brown, Founder of Black Book Research. 'Vendors delivering real-time, AI-powered solutions will define the next generation of care access efficiency for providers, payers, and patients alike.' About Black Book Research Black Book Research is a leading healthcare IT research firm known for its independent, vendor-agnostic approach. Over the past 15 years, Black Book has collected over 3 million survey responses from nearly 500,000 healthcare professionals. The firm's flash surveys and long-form evaluations provide real-time, unbiased insights that support strategic decision-making across the healthcare ecosystem. Visit or contact [email protected] for full survey results and vendor-specific performance details. Contact InformationPress Office 8008637590 SOURCE: Black Book Research press release